Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation

Jingbo Yu, Shreekant Parasuraman, Anshul Shah, Daniel Weisdorf

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Acute graft-versus-host disease (aGVHD) is a common and life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The extent to which aGVHD increases inpatient costs associated with allo-HSCT has not been thoroughly evaluated. In this analysis, mortality, hospital length of stay (LOS) and costs associated with aGVHD during allo-HSCT admissions are evaluated. Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge. Results: Overall, mortality (16.2% vs. 5.3%; p <.01), median hospital LOS (42.0 vs. 26.0 days; p <.01) and median total costs ($173,144 vs. $98,982; p <.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups. Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT.

Original languageEnglish (US)
Pages (from-to)983-988
Number of pages6
JournalCurrent Medical Research and Opinion
Volume35
Issue number6
DOIs
StatePublished - Jun 3 2019

Fingerprint

Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Length of Stay
Hospitalization
Costs and Cost Analysis
Mortality
Hospital Costs
Inpatients
Survival
Health Care Costs
Age Groups
Databases

Keywords

  • Hematopoietic stem cell transplantation
  • graft-versus-host disease
  • healthcare costs
  • resource utilization

Cite this

Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation. / Yu, Jingbo; Parasuraman, Shreekant; Shah, Anshul; Weisdorf, Daniel.

In: Current Medical Research and Opinion, Vol. 35, No. 6, 03.06.2019, p. 983-988.

Research output: Contribution to journalArticle

@article{d1318be3d7e94c419345365f42ce6d34,
title = "Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation",
abstract = "Objective: Acute graft-versus-host disease (aGVHD) is a common and life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The extent to which aGVHD increases inpatient costs associated with allo-HSCT has not been thoroughly evaluated. In this analysis, mortality, hospital length of stay (LOS) and costs associated with aGVHD during allo-HSCT admissions are evaluated. Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge. Results: Overall, mortality (16.2{\%} vs. 5.3{\%}; p <.01), median hospital LOS (42.0 vs. 26.0 days; p <.01) and median total costs ($173,144 vs. $98,982; p <.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups. Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT.",
keywords = "Hematopoietic stem cell transplantation, graft-versus-host disease, healthcare costs, resource utilization",
author = "Jingbo Yu and Shreekant Parasuraman and Anshul Shah and Daniel Weisdorf",
year = "2019",
month = "6",
day = "3",
doi = "10.1080/03007995.2018.1551193",
language = "English (US)",
volume = "35",
pages = "983--988",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation

AU - Yu, Jingbo

AU - Parasuraman, Shreekant

AU - Shah, Anshul

AU - Weisdorf, Daniel

PY - 2019/6/3

Y1 - 2019/6/3

N2 - Objective: Acute graft-versus-host disease (aGVHD) is a common and life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The extent to which aGVHD increases inpatient costs associated with allo-HSCT has not been thoroughly evaluated. In this analysis, mortality, hospital length of stay (LOS) and costs associated with aGVHD during allo-HSCT admissions are evaluated. Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge. Results: Overall, mortality (16.2% vs. 5.3%; p <.01), median hospital LOS (42.0 vs. 26.0 days; p <.01) and median total costs ($173,144 vs. $98,982; p <.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups. Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT.

AB - Objective: Acute graft-versus-host disease (aGVHD) is a common and life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The extent to which aGVHD increases inpatient costs associated with allo-HSCT has not been thoroughly evaluated. In this analysis, mortality, hospital length of stay (LOS) and costs associated with aGVHD during allo-HSCT admissions are evaluated. Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge. Results: Overall, mortality (16.2% vs. 5.3%; p <.01), median hospital LOS (42.0 vs. 26.0 days; p <.01) and median total costs ($173,144 vs. $98,982; p <.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups. Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT.

KW - Hematopoietic stem cell transplantation

KW - graft-versus-host disease

KW - healthcare costs

KW - resource utilization

UR - http://www.scopus.com/inward/record.url?scp=85059007502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059007502&partnerID=8YFLogxK

U2 - 10.1080/03007995.2018.1551193

DO - 10.1080/03007995.2018.1551193

M3 - Article

C2 - 30461314

AN - SCOPUS:85059007502

VL - 35

SP - 983

EP - 988

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 6

ER -